-+ 0.00%
-+ 0.00%
-+ 0.00%

Autonomix Medical announces standalone neural sensing platform after preclinical renal nerve activity results

PUBT·06/22/2026 12:02:36
Listen to the news
Autonomix Medical announces standalone neural sensing platform after preclinical renal nerve activity results
  • Autonomix unveiled a standalone neural sensing platform for renal denervation, citing preclinical evidence of real-time renal nerve activity changes.
  • Findings were presented as recent preclinical study results; no future presentation timing was disclosed.
  • Work suggests the system can detect nerve signals during blood-pressure shifts, supporting feedback-guided procedures to improve consistency.
  • Strategy targets expansion into the cardiovascular market, with a potential Class II diagnostic regulatory pathway.
  • Program runs in parallel with its lead pancreatic cancer pain clinical effort, using the same core sensing technology to broaden commercial optionality.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750097) on June 22, 2026, and is solely responsible for the information contained therein.